Reaction

Vitreous Haemorrhage reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,738 reports · 53 co-occurring drugs

As of the last recalculation, Vitreous Haemorrhage appears in 2,738 FAERS reports alongside 53 co-occurring drug terms. The strongest observed disproportionality signal is RANIBIZUMAB (PRR 155.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ranibizumab	454	155.7	158.4
Aflibercept	274	74.1	74.7
Faricimab	46	43.9	44.1
Melphalan Hydrochloride	116	36.7	36.8
Melphalan	80	27.5	27.6
Prednisolone Acetate	29	21.5	21.6
Alteplase	40	20.5	20.6
Bevacizumab	238	15.9	15.9
Ganciclovir	20	15.0	15.0
Ganciclovir Sodium	20	14.5	14.5
Brimonidine Tartrate	33	14.2	14.3
Timolol Maleate	16	12.3	12.4
Atropine Sulfate	17	12.0	12.0
Dorzolamide Hydrochloride And Timolol Maleate	12	11.6	11.6
Timolol	18	11.4	11.4
Atropine	12	11.1	11.1
Insulin	71	9.9	9.9
Moxifloxacin Hydrochloride	25	9.5	9.5
Fondaparinux Sodium	10	9.4	9.4
Dexamethasone Sodium Phosphate	11	8.3	8.3
Brinzolamide	9	7.9	7.9
Clopidogrel Bisulfate	95	7.3	7.3
Triamcinolone Acetonide Ointment Usp, 0.05%	22	7.2	7.2
Human Insulin	11	6.7	6.7
Cladribine	8	6.3	6.3
Latanoprost	39	6.0	6.0
Bupivacaine	7	5.7	5.7
Triamcinolone Acetonide	23	5.7	5.7
Valganciclovir Hydrochloride Powder,	9	5.6	5.6
Clopidogrel	133	5.3	5.3
Tobramycin Sulfate	8	4.9	4.9
Insulin Human	24	4.6	4.6
Ibrutinib	48	4.6	4.6
Insulin Glulisine	6	4.5	4.5
Tobramycin Solution	7	4.4	4.4
Oral Semaglutide	38	4.0	4.0
Carboplatin	63	3.8	3.8
Apixaban	33	3.8	3.8
Etoposide	36	3.8	3.8
Dexamethasone	140	3.7	3.7
Rivaroxaban	99	3.7	3.7
Bimatoprost	14	3.7	3.7
Imatinib Mesylate	13	3.6	3.6
Insulin Glargine	108	3.4	3.4
Tobramycin	10	3.2	3.2
Dabigatran Etexilate	32	3.2	3.2
Dabigatran Etexilate Mesylate	29	3.1	3.1
Insulin Lispro	54	3.0	3.0
Methoxy Polyethylene Glycol-Epoetin Beta	4	2.8	2.8
Vemurafenib	4	2.5	2.5
Cortisone Acetate	4	2.5	2.5
Cannabidiol	7	2.3	2.3
Tirzepatide	17	0.8	0.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.